An additional 500 jobs will be created by JSE-listed Aspen Pharmacare’s new R1bn facility in Port Elizabeth, where the pharmaceutical manufacturer will produce specialised products for chronic conditions, including certain cancers. The official opening on Monday marked a shift for Aspen from commodity generics into specialised products with niche markets. The additional 500 jobs will add to the more than 2,000 jobs at the listed company’s flagship site in Port Elizabeth. The group employs more than 10,000 people globally, 40% of whom are employed in SA. Aspen is also in the process of establishing a training academy to give its employees the opportunity to attain national accredited qualifications in pharmaceutical manufacture. Initial production at the facility is planned for Alkeran, Leukeran and Purinethol (treatment of late-stage cancers); Imuran (prevention of organ tissue rejection in liver and kidney transplants, as well as treatment of certain auto-immune diseases); and Benz...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, Morningstar financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00.